Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sinopharm in Hunt for $3 Billion German Generic Drug Company

publication date: Dec 8, 2009
Sinopharm Group Co. survived the first round of bidding for German generic-drug maker Radiopharm GmbH and could be a winner in the auction to acquire the company, as second-round bids were submitted last week. It was joined by fellow drug companies Teva Pharmaceuticals (NSDQ: TEVA) and Sanofi-Aventis (NYSE: SNY) and as many as three other companies, according to a story in Bloomberg News. Minimum bids of the four to six surviving bidders are expected to be 2 billion euros ($3 billion). More details...

Stock Symbol: (HK: 01099)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital